Yoram Drucker

Executive Officer, Director at NurExone Biologic.

NurExone Biologic

Raised on NurExone Biologic filings

$2.2M

of $4.4M offered across 3 Form D filings

Form D filings: 3
Teammates: 6
Last filing: Jul 2, 2026

Company

NurExone Biologic

Biotech

Exosome drug for acute spinal cord injury

Exosome drug for acute spinal cord injury

Investors: 1
Still open: $2.2M

Investors: 1
Sector: Biotech

NurExone Biologic filings

NurExone Biologic Form D filings
Filed	Security	Sold of offered	Filing
Jul 2, 2026	Equity	$442K/ $442K	Form D
Aug 27, 2025	Equity	$148K/ $243K	Form D
Apr 22, 2025	Equity	$1.6M/ $3.8M	Form D

EquityFiled Jul 2, 2026Form D
$442K/ $442K
EquityFiled Aug 27, 2025Form D
$148K/ $243K
EquityFiled Apr 22, 2025Form D
$1.6M/ $3.8M

Works with

Also named on NurExone Biologic filings

Eran OvadyaChief Financial Officer, Form D signerForm D signer Gadi RiesenfeldDirector Eyal GabbaiDirector James RichardsonDirector Lior ShaltielExecutive Officer, Director Oded OrgilDirector